Creativity in drug development
CEO Lisa Patel wants to invite patients to the table and put their everyday experiences of living with chronic diseases at the forefront of future drug development.
16th October 2023
An important conversation
CEO Lisa Patel wants to invite patients to the table and put their everyday experiences of living with chronic diseases at the forefront of future drug development.
17th August 2023
A new approach to tackling chronic disease
CEO Lisa Patel discusses our approach to tackling chronic disease....
17th August 2023
CEO Lisa Patel features on 15 minutes with the doctor
Our CEO Lisa Patel booked an ‘appointment’ with Dr Vinay...
21st June 2023
CEO Lisa Patel explores the perception of ‘easy diseases’
What does it mean for a disease to be ‘easy’, and how do we define when a disease is ‘solved’?
19th May 2023
Istesso announces FDA Fast Track and Orphan Drug designation for MBS2320
Istesso Limited, the programmed disease resolution company, today announces that...
5th December 2022
CEO Lisa Patel on Careers in Discovery
Our CEO Lisa Patel was recently featured on Tom Froggatt’s...
30th November 2022
MBS2320 administered to participants with moderate-to-severe Rheumatoid Arthritis
Istesso Limited, the programmed disease resolution company, today announces the...
6th September 2022
Potential of Istesso’s MBS2320 hits the headlines
Istesso Limited (“Istesso’’) was featured on Thisismoney.co.uk over the weekend,...
30th August 2022